| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.08. | Ortivus AB Ser. B Q2 Loss Decreases | 1 | RTTNews | ||
| 25.08. | Ortivus AB: Interim Report for Ortivus AB (publ) for the period April - June 2026 | 177 | GlobeNewswire (Europe) | "Ortivus' deep domain knowledge and advancements in AI mean that we, with the MobiMed platform, are well positioned to meet the healthcare sector's urgent need for increased efficiency."
April-June... ► Artikel lesen | |
| 07.05. | Ortivus AB: Interim Report for Ortivus AB (publ) for the period January-March 2026 | 248 | GlobeNewswire (Europe) | "We are fully embracing AI, both in our products and in our internal operations."
January-March 2026 Net sales increased with 18% and amounted to SEK 21.5 (18.1) million.The gross margin increased to... ► Artikel lesen | |
| ORTIVUS Aktie jetzt für 0€ handeln | |||||
| 04.05. | Ortivus AB: Ortivus AB completes sale of its holding in H&E Solutions AB and realises a profit | 243 | GlobeNewswire (Europe) | Ortivus AB today announces that it has completed the sale of its entire shareholding in the technology company H&E Solutions AB (Evam) for a purchase price of SEK 5.2 million. The transaction results... ► Artikel lesen | |
| 21.04. | Ortivus AB: Ortivus AB welcomes Matti Zemack as new Chief Product Officer | 375 | GlobeNewswire (Europe) | Ortivus is pleased to announce the appointment of Matti Zemack as the new Chief Product Officer (CPO). In this strategic role, Zemack will lead the company's product vision and development, driving... ► Artikel lesen | |
| 31.03. | Ortivus AB: Ortivus strengthens liquidity to accelerate the company's growth strategy | 228 | GlobeNewswire (Europe) | Ortivus is enabling increased investment in its growth strategy by further strengthening its financial position with an additional loan of SEK 5 million, following the full utilisation of the SEK 20... ► Artikel lesen | |
| 19.02. | Ortivus AB: Year-end Report January - December 2025 | 336 | GlobeNewswire (Europe) | "We enter 2026 with a strengthened balance sheet, a more efficient organisation, and a portfolio of innovations already making a difference."
October-December 2025Net sales decreased by 12% and amounted... ► Artikel lesen | |
| 13.01. | The observation status for Ortivus AB is removed | 494 | GlobeNewswire | On December 2, 2025, the shares in Ortivus AB (the "Company") were given observation status with reference to a mandatory public offer from Ponderus Invest AB to the other shareholders in Ortivus... ► Artikel lesen | |
| 13.01. | Ortivus AB: Ortivus informs that Ponderus Invest AB has announced the final outcome of the mandatory cash offer to the shareholders of Ortivus Aktiebolag | 294 | GlobeNewswire (Europe) | Ponderus Invest AB ("Ponderus") announced on 2 December 2025 a mandatory cash offer to the shareholders of Ortivus Aktiebolag ("Ortivus" or the "Company") to transfer all of their shares in Ortivus... ► Artikel lesen | |
| 22.12.25 | Ortivus AB: Ortivus informs that Ponderus Invest AB has announced approval from the Swedish Inspectorate of Strategic Products regarding the mandatory cash offer to the shareholders of Ortivus Aktiebolag | 256 | GlobeNewswire (Europe) | Ponderus Invest AB ("Ponderus") announced on 2 December 2025 a mandatory cash offer to the shareholders of Ortivus Aktiebolag ("Ortivus") to transfer all of their shares in Ortivus to Ponderus for SEK... ► Artikel lesen | |
| 18.12.25 | Ortivus AB: The independent bid committee of Ortivus unanimously recommends that shareholders do not accept the mandatory cash offer submitted by Ponderus Invest AB | 336 | GlobeNewswire (Europe) | The independent bid committee of Ortivus AB (publ) ("Ortivus" or the "Company") unanimously recommends that shareholders of Ortivus do not accept the mandatory cash offer submitted by Ponderus Invest... ► Artikel lesen | |
| 17.12.25 | Ortivus AB: Ortivus welcomes Minni Raij as new CFO | 300 | GlobeNewswire (Europe) | Ortivus is pleased to announce the appointment of Minni Raij as the new Chief Financial Officer (CFO) at Ortivus. Minni brings more than two decades of experience in finance and management. Minni will... ► Artikel lesen | |
| 02.12.25 | Ortivus AB receives observation status | 240 | GlobeNewswire | Today, December 2, 2025, Ponderus Invest AB disclosed a mandatory public offer to the other shareholders in Ortivus AB.
The rules of Nasdaq First North Growth Market state that an issuer may... ► Artikel lesen | |
| 02.12.25 | Ortivus AB: Ortivus announces mandatory public offer from Ponderus Invest AB | 237 | GlobeNewswire (Europe) | On 14 November 2025, Ponderus Invest AB announced its intention to return no later than 3 December 2025 with information regarding a potential mandatory public offer to the shareholders of Ortivus AB... ► Artikel lesen | |
| 28.11.25 | Ortivus AB: Interim Report for Ortivus AB (publ) for the period July - September 2025 | 371 | GlobeNewswire (Europe) | "The increased interest we are witnessing in the market and from existing customers, together with the high pace of our product development, gives us a positive outlook for the future."
July-September... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS MEDICAL CARE | 38,560 | -2,90 % | EQS-News: Fresenius SE & Co. KGaA: Fresenius schließt Verkauf von 13,4 Millionen Aktien der Fresenius Medical Care zu 39,00 Euro je Aktie ab und erzielt rund 524 Millionen Euro | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Beteiligung/Unternehmensbeteiligung
Fresenius schließt Verkauf von 13,4 Millionen Aktien der Fresenius Medical Care zu 39,00... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 43,840 | +1,25 % | Aktie zieht an!: Siemens liefert und legt nach, die Strategie überzeugt wirft Fragen auf | © Foto: Joko - JokoSiemens meldet Rekordzahlen und hebt die Mittelfristziele an. Anleger bleiben trotzdem skeptisch, denn die neue Konzernstrategie gilt vielen noch als zu unscharf Enthaltene Werte:... ► Artikel lesen | |
| FRESENIUS | 53,43 | -0,60 % | Fresenius-Aktie und BASF-Aktie: Aktuelle Einschätzungen im Fokus | Die Aktien von Fresenius und BASF stehen im Anlegerfokus. Während Fresenius mit starken Quartalszahlen, steigender Profitabilität und neuen Kursrekorden überzeugt, setzt BASF auf eine Belebung des globalen... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 24,600 | 0,00 % | Privia Health Group, Inc.: Privia Health Reports Strong Results in the 2025 Performance Year of the Medicare Shared Savings Program | ||
| BILLIONTOONE | 91,50 | -0,04 % | BillionToOne weist Vorwürfe aus Leerverkäufer-Bericht zurück | ||
| BRIGHTSPRING HEALTH SERVICES | 68,35 | +0,01 % | BMO raises BrightSpring Health stock price target on LDD momentum | ||
| GENEDX | 52,19 | +0,44 % | GeneDx Taps Everett Cunningham as CEO | ||
| LIFESTANCE HEALTH GROUP | 13,785 | +0,11 % | LifeStance Health Group, Inc.: LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook | SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 32,260 | -6,22 % | Carl Zeiss Meditec-Aktie -3%: Jetzt die Reißleine ziehen? | Die Aktie von Carl Zeiss Meditec gab am Mittwoch zeitweise mehr als 3% nach, FMC verlor im Dax bis zu 2%. Beide Titel konnten sich damit der Stabilisierung am Gesamtmarkt nicht anschließen, Auslöser... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 6,735 | +0,22 % | Alignment Healthcare falls 9% amid weakness in Medicare Advantage stocks | ||
| GERRESHEIMER | 33,200 | +3,81 % | Gerresheimer: Jetzt muss das Schlussquartal liefern | ||
| HEARTFLOW | 45,905 | 0,00 % | Heartflow stock tumbles despite strong growth beating Q3 expectations | ||
| ARDENT HEALTH | 14,370 | -0,14 % | Ardent Health Stock Falls 20% After Secondary Offering Price Set | ||
| PROCEPT BIOROBOTICS | 25,190 | 0,00 % | Procept BioRobotics outlines $390M-$410M 2026 revenue, while targeting positive adjusted EBITDA in Q4 | ||
| OTTOBOCK | 37,750 | -1,56 % | Ottobock-Aktie -10%: Wer will +50 bis +100% Gewinn machen? | Es ist ein rabenschwarzer Tag für die Ottobock-Aktie. Mit einem herben Kursverlust von -10% ist der deutsche Medtechkonzern nicht nur eines der Schlusslichter im SDAX, sondern fällt auch auf ein neues... ► Artikel lesen |